



## ***Publication of 2014 Reference Document and Annual Report***

**Paris (France), Copenhagen (Denmark), April 14, 2015** – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced the publication of its 2014 Reference Document and Annual Report.

The 2014 Reference Document, registered this day with the French Market Authorities (Autorité des Marchés Financiers), is available to the public free of charge upon request as per current legal regulations at Onxeo's headquarters - 49 Boulevard du Général Martial Valin, 75015 Paris - and may be consulted on the company's website at <http://www.onxeo.com/en/investisseurs/>.

The annual financial report, the report of the Chairman of the Board of Directors on corporate governance and on internal control and risk management procedures, as well as the related auditors' report, Information on the fees paid to the statutory auditors in 2014, are included in this Reference Document.

Additionally, Onxeo's 2014 Annual Report is also available on the Company's website at <http://www.onxeo.com/en/investisseurs/>.

### **About Onxeo**

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference". The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

### ***Key orphan oncology products at the advanced development stage are:***

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma

Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results

Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

*For more information, visit the website [www.onxeo.com](http://www.onxeo.com)*

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website ([www.onxeo.com](http://www.onxeo.com)).*

**Contacts :**

Judith Greciet, CEO  
j.greciet@onxeo.com  
Nicolas Fellmann, CFO  
n.fellmann@onxeo.com  
+33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP  
onxeo@alizerp.com  
+33 6 64 18 99 59 / +33 1 44 54 36 62